" class="no-js "lang="en-US"> Swing Therapeutics Selects Curavit to Provide Virtual Trial Site Services for Novel Digital Therapeutic Study for Fibromyalgia - Pharmtech Focus
Friday, January 27, 2023

Swing Therapeutics Selects Curavit to Provide Virtual Trial Site Services for Novel Digital Therapeutic Study for Fibromyalgia

Curavit Clinical Researcha virtual contract research organization (VCRO), has been selected by digital therapeutics company, Swing Therapeutics to be a virtual site for its pivotal trial of an investigational digital therapeutic (DTx) for fibromyalgia. Curavit will remotely recruit, screen, consent, and enroll participants in Swing’s PROSPER-FM randomized clinical trial from across the United States. Curavit will then manage participants throughout the 12-week clinical trial. By eliminating physical and geographic barriers to trial participation and execution, Curavit can scale quickly and improve patient enrollment by at least 10x over a traditional trial, speeding trial execution.

Fibromyalgia is a chronic and debilitating pain condition that affects more than 10 million Americans. It is characterized by widespread musculoskeletal pain often accompanied by fatigue, sleep, memory and mood disruptions. Swing developed its digital therapeutic with the goal of providing an accessible behavioral therapy option that can be used alongside medication, physical therapy, and other standard-of-care treatments.

“We are focused on getting patient recruitment right,” said Mike Rosenbluth, PhD, Chief Executive Officer at Swing, which recently announced a $10M Series A funding round. “Curavit’s virtual services model enables us to efficiently recruit participants representative of the entire patient population. It solves a huge challenge and will be critical to rapidly develop the evidence needed to bring an effective digital therapy to millions suffering from chronic illness.”

Swing marks Curavit’s 10th DTx client signed in less than six months, a trend in line with a booming global DTx market projected to hit $13.1 billion by 2026, up from $3.4 billion in 2021. Curavit’s decentralized clinical trial (DCT) expertise makes the company well-suited to support prescription and non-prescription DTx studies. Fundamentally, there are no physical logistics with a DTx – no shipping, storing, chain of control, cold storage, or biohazards plus endpoints can often be captured within the DTx application itself, naturally aligning DCTs with DTx studies.

“Swing is committed to developing scientifically backed digital treatments and evidence to clinically validate their use in the real world, making representative patient participation critical,” said Joel Morse, co-founder and CEO of Curavit. “Our operational model prioritizes patient recruitment and removes geographic boundaries to expand the pool without the expense of physical infrastructure. With zero physical site visits, too, patients are less burdened and more likely to stick with the trial the duration.”

People In This Post

Companies In This Post

  1. Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Read more
  2. Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO Chews for Dogs Read more
  3. Sharecare Launches VR Program to Improve Well-being of American Workforce Read more
  4. Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer Read more
  5. Nogra Pharma Announces Out-licensing Agreement with Torii Pharmaceutical for Japan for New Chemical Entity Topical Acne Treatment Read more